Can Rhinoviruses Cause Severe Pneumonia?
Yes, rhinoviruses can definitively cause severe pneumonia in adults and children, particularly in immunocompromised patients, those with comorbidities, and during co-infections with bacterial pathogens.
Evidence from Guidelines
The 2021 American Thoracic Society guidelines explicitly state that rhinovirus/enterovirus may cause severe pneumonia in adult patients 1. The guidelines acknowledge that noninfluenza respiratory viruses, including rhinovirus, are detected in 9-41% of severe community-acquired pneumonia (CAP) cases and have been associated with increased need for mechanical ventilation, prolonged ICU support, and increased mortality 1.
The 2013 ECIL-4 guidelines confirm that in allogeneic hematopoietic stem cell transplant (HSCT) recipients, rhinoviruses are the most frequently detected community-acquired respiratory viruses, with cumulative incidence reaching 22.3% by day 100 post-transplant 2. While lower respiratory tract disease with frank pneumonia is rare in this population (occurring in <10% of infected patients), it carries an estimated mortality of <10% 2.
High-Risk Populations
Immunocompromised Patients
- HSCT recipients have the highest risk, with rhinovirus being their most common viral respiratory pathogen 2
- Lung transplant recipients are at elevated risk for progression from upper to lower respiratory tract infection 1
- Patients with malignancy show increased risk of mortality and critical care admission with moderate certainty 3
Patients with Comorbidities
- Any comorbidity or pulmonary comorbidity is probably associated with increased risk of lower respiratory tract infection with moderate certainty 3
- Diabetes mellitus is NOT associated with increased mortality (high certainty) 3
Age Considerations
- Age <1 year and premature birth are NOT associated with increased risk of lower respiratory tract infection (high certainty) 3
- Age >18 years is probably associated with increased mortality risk (moderate certainty) 3
- In children, severe rhinovirus pneumonia occurs more frequently in older preschool and school-age children (mean age 5.2 years vs 3.7 years for mild cases) 4
Recent Direct Evidence of Pathogenicity
A 2026 retrospective study provided the first histological evidence of rhinovirus infection in lower respiratory tract cells of immunocompetent adults 5. Using immunofluorescence staining on transbronchial lung biopsy specimens, rhinovirus VP3 protein was confirmed in 61.5% (8/13) of cases, definitively resolving debates about rhinovirus's capacity to directly infect alveolar cells 5.
Among 437 hospitalized adults with rhinovirus detection, 224 developed pneumonia, with 34 (7.8%) meeting criteria for simple viral pneumonia 5. Independent predictors of rhinovirus pneumonia were:
- Male sex (OR 2.69,95% CI 1.04-6.99)
- Fever (OR 3.79,95% CI 1.52-9.44)
- Cough (OR 7.33,95% CI 1.64-32.83)
Co-infection as a Critical Factor
Co-infection with bacterial pathogens significantly increases severity. In the 2026 adult study, 49% of rhinovirus-positive patients had co-infections, predominantly bacterial (34.1%) 5.
In children, co-infection with Streptococcus pneumoniae or Mycoplasma pneumoniae is an independent risk factor for severe rhinovirus pneumonia 4:
- Streptococcus pneumoniae co-infection: OR 1.611 (95% CI 1.066-2.435)
- Mycoplasma co-infection: OR 3.355 (95% CI 2.062-5.458)
A 2023 pediatric study found that all rhinovirus-positive children with pneumonia had markers strongly indicating bacterial co-infection (elevated WBC, CRP, procalcitonin, or alveolar changes) 6.
Clinical Markers of Severity
Laboratory Findings
Severe rhinovirus pneumonia correlates with:
- Elevated lactate dehydrogenase (LDH) (correlation coefficient 0.198) 4
- Elevated C-reactive protein (correlation coefficient 0.334) 4
- Elevated neutrophils (correlation coefficient 0.104) 4
- Decreased albumin (correlation coefficient 0.308) 4
- Elevated creatinine (correlation coefficient 0.142) 4
Viral Load
High rhinovirus loads (low cycle threshold values, median 23.2) indicate active infection and correlate with symptomatic presentations 5, 6.
Biomarker Distinction
Low myxovirus resistance protein A (MxA) levels distinguish rhinovirus pneumonia from other viral pneumonias 6:
- Rhinovirus pneumonia: median MxA 100 μg/L
- Other viral pneumonias: median MxA 495 μg/L (p=0.034)
- Rhinovirus upper respiratory infection: median MxA 620 μg/L (p=0.011)
This suggests true viral-bacterial co-infection rather than pure viral pneumonia in most rhinovirus cases.
Mortality Data
A 2022 pediatric study of mechanically ventilated patients with severe pneumonia found rhinovirus was the most common virus detected (32.1%), with an overall mortality rate of 56.36% among viral-associated severe pneumonia 7. Odds of mortality increased threefold with comorbid conditions and tenfold with congenital heart disease 7.
Clinical Implications
Testing Recommendations
The ATS guidelines suggest considering nucleic acid-based testing for rhinovirus in:
- Immunocompromised patients at high risk for death from respiratory viral infection 1
- Patients with severe CAP requiring mechanical ventilation or vasopressors 1
Treatment Limitations
No clinically available antiviral agents exist for rhinovirus 1. Management remains supportive, though detection may become more relevant as effective antivirals are developed 1.
Common Pitfall
Do not dismiss rhinovirus detection as mere colonization or upper respiratory infection in hospitalized patients with pneumonia. The histological evidence of lower respiratory tract cell infection 5, high viral loads, rapid clearance patterns, and association with severe outcomes demonstrate true pathogenicity, particularly when bacterial co-infection markers are present.